Eli Lilly and Company (NYSE:LLY) Shares Climb 6.5% After Earnings Beat

Eli Lilly and Company (NYSE:LLY)’s stock price was up 6.5% on Thursday after the company announced better than expected quarterly earnings. The stock traded as high as $1,408.38 and last traded at $1,372.01. Approximately 4,350,276 shares traded hands during trading, an increase of 48% from the average session volume of 2,933,143 shares. The stock had previously closed at $1,288.30.

The company reported $7.48 EPS for the quarter, topping analysts’ consensus estimates of $5.68 by $1.80. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company had revenue of $24.40 billion for the quarter, compared to the consensus estimate of $22.58 billion. During the same period in the previous year, the firm earned $7.02 EPS. Eli Lilly and Company’s revenue was up 38.6% on a year-over-year basis.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 23.22%.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong earnings and revenue beat: Third-quarter revenue rose 39% year over year to $24.4 billion, above the roughly $22.6 billion analyst estimate. Adjusted EPS was $7.48, well ahead of the $5.68 consensus and up from $7.02 a year earlier. Reuters earnings and outlook article
• Positive Sentiment: Higher full-year outlook: Lilly raised its 2026 revenue forecast to $91 billion-$92 billion from $85 billion-$87 billion, lifting the midpoint by $5.5 billion. The increase signals that demand for its metabolic-care portfolio is exceeding prior expectations. Lilly third-quarter results and guidance
• Positive Sentiment: Mounjaro and Zepbound remain major growth engines: Mounjaro sales jumped 65% to $10.7 billion, while Zepbound revenue increased 49% to $5.35 billion. The results reinforced investor confidence in Lilly’s leadership of the diabetes and obesity-drug market. New York Post weight-loss drug demand article
• Positive Sentiment: Pipeline momentum improved: Phase 3 data showed experimental drug retatrutide produced greater A1C reduction and more than twice the weight loss of Ozempic 2 mg in adults with type 2 diabetes. The data strengthen Lilly’s competitive position against Novo Nordisk and support longer-term growth expectations. Lilly retatrutide trial results
• Neutral Sentiment: Investors should watch earnings quality: Quarterly revenue benefited from approximately $900 million in Jardiance milestones and rebate-related adjustments. Lilly also recorded substantial acquired in-process research and development charges, while reports noted a trimmed profit view tied to deal-related costs.
• Negative Sentiment: Insider selling is a secondary risk signal: Four Lilly executives sold shares during the past six months, with no reported open-market purchases. These transactions have not outweighed the earnings-driven optimism but may draw attention given the stock’s elevated valuation.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on LLY shares. Bank of America lifted their target price on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Wall Street Zen lowered Eli Lilly and Company from a “buy” rating to a “hold” rating in a research report on Saturday, October 17th. Weiss Ratings raised Eli Lilly and Company from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday, October 15th. Guggenheim upped their target price on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a “buy” rating in a report on Friday, September 18th. Finally, BMO Capital Markets restated an “outperform” rating on shares of Eli Lilly and Company in a report on Thursday, October 1st. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $1,320.25.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the sale, the executive vice president directly owned 54,147 shares in the company, valued at $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the transaction, the chief accounting officer directly owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 13,500 shares of company stock valued at $15,958,170. Company insiders own 0.14% of the company’s stock.

Institutional Investors Weigh In On Eli Lilly and Company

A number of large investors have recently bought and sold shares of LLY. Trek Financial LLC boosted its position in Eli Lilly and Company by 10.3% in the 3rd quarter. Trek Financial LLC now owns 4,059 shares of the company’s stock valued at $4,697,000 after buying an additional 380 shares during the last quarter. Woodmont Investment Counsel LLC boosted its holdings in Eli Lilly and Company by 1.3% during the third quarter. Woodmont Investment Counsel LLC now owns 22,467 shares of the company’s stock worth $25,997,000 after buying an additional 284 shares during the last quarter. Traynor Capital Management Inc. boosted its stake in Eli Lilly and Company by 1.1% during the 3rd quarter. Traynor Capital Management Inc. now owns 55,402 shares of the company’s stock worth $64,104,000 after acquiring an additional 588 shares during the last quarter. Walled Lake Planning & Wealth Management LLC boosted its position in shares of Eli Lilly and Company by 12.9% during the third quarter. Walled Lake Planning & Wealth Management LLC now owns 641 shares of the company’s stock worth $742,000 after purchasing an additional 73 shares in the last quarter. Finally, Virtue Capital Management LLC increased its position in shares of Eli Lilly and Company by 40.3% in the 3rd quarter. Virtue Capital Management LLC now owns 926 shares of the company’s stock valued at $1,072,000 after buying an additional 266 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Trading Up 6.5%

The stock has a market capitalization of $1.29 trillion, a price-to-earnings ratio of 46.04, a PEG ratio of 1.71 and a beta of 0.46. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The business has a 50 day simple moving average of $1,192.52 and a 200-day simple moving average of $1,089.35.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.